Each week we highlight five things affecting the life sciences industry. Here’s the latest.
Medtech M&A has remained strong through the first half of 2026
- So far 2026 has seen multiple large-scale deals led by major strategics, including blockbuster transactions in the medtech sector.
- Activity spans both acquisitions and divestitures, as companies actively reshape portfolios, buying into high-growth areas like cardiovascular, cancer tech and robotics while spinning off non-core businesses, reports Medtech Dive.
EU push for unified pharma framework amid rising U.S. pricing pressure
- Five European countries are calling for a unified European Union-wide pharmaceutical framework to address affordability and access to innovative medicines, emphasizing coordination amid geopolitical pressures rather than fragmented national policies.
- According to Fierce Pharma, the push comes as U.S. drug pricing pressure and recent European cost-cutting measures (e.g., Germany reforms) are straining pharma investment, with companies scaling back spending and governments exploring coordinated responses to maintain competitiveness and patient access.
Largest biotech IPO announced
- A biotech company raised $670 million in its initial public offering (plus $75 million private investment), marking the largest biotech IPO ever, signaling continued investor appetite for biotech, despite competition from large upcoming artificial intelligence IPOs, reports Endpoints News.
- Proceeds will fund late-stage development of the company’s cancer drug for desmoid tumors, with Phase 3 trials planned next year as oncology biotech regains momentum amid recent industry deals and data releases.
A heart health company launches plans for a ~$320 million IPO
- With an expected IPO of 23.3 million shares priced at $14–$16, a heart health company is part of a broader comeback in biotech listings.
- It joins roughly 13 U.S. biotech IPOs this year, signaling improving capital markets after the pandemic-era boom. The company is advancing three late-stage, in-licensed cardiovascular drugs, reports Endpoints News.
Biopharma company deal indicates refreshed oncology ambitions
- A biopharma company’s acquisition of a Boston-based oncology company for $10.6 billion marks a significant shift under its new chief executive officer, likely indicating a more aggressive push to rebuild the company’s oncology business after exiting the space more than a decade ago, reports The Wall Street Journal.
- The Boston-based organization will bring three key lung cancer programs to the biopharma company’s pipeline as the purchase indicates both a shift in oncology strategy and wider business strategy to meet ambitious growth targets.
For more insights in life sciences, check out RSM’s industry outlook.
